RxDoctor Payments Data

Todd Lackney, DO

Internal Medicine · Danville, KYNPI 1619938974

Payments from drug & device makers

$981in general payments, 2019–2025

Across 53 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$260
  • AbbVie$260
  • Novo Nordisk$86
  • Lilly USA, LLC$68
  • Amgen$44
  • Antares Pharma, Inc.$35
  • plus $227 from 11 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$981 in reported general payments places this provider in the 60th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$11,726
Medicare patients
58
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$134,833
OzempicSemaglutide39$36,297
XareltoRivaroxaban52$35,757
MounjaroTirzepatide25$34,135
Repatha SureclickEvolocumab34$33,878
MyrbetriqMirabegron75$33,636
JardianceEmpagliflozin35$29,302
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$19,404
CreonLipase/Protease/Amylase19$18,315
LinzessLinaclotide27$16,681
TrulicityDulaglutide13$12,287
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,283
JanuviaSitagliptin Phosphate18$12,022
Breo ElliptaFluticasone/Vilanterol28$11,881
PremarinEstrogens, Conjugated23$7,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$68$46,42338 claims
AbbVieCreon, Linzess, Lumigan$260$38,67660 claims
Novo NordiskOzempic$86$36,29739 claims
Astellas Pharma US IncMyrbetriq$14$33,63675 claims
Boehringer IngelheimJardiance$30$29,30235 claims
GSKTrelegy Ellipta, Breo Ellipta$18$24,16447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →